NASDAQ:TRVI Trevi Therapeutics Q1 2023 Earnings Report $6.07 -0.03 (-0.49%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$6.04 -0.03 (-0.41%) As of 04/17/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Trevi Therapeutics EPS ResultsActual EPS-$0.06Consensus EPS -$0.08Beat/MissBeat by +$0.02One Year Ago EPSN/ATrevi Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATrevi Therapeutics Announcement DetailsQuarterQ1 2023Date5/11/2023TimeN/AConference Call DateThursday, May 11, 2023Conference Call Time4:30PM ETUpcoming EarningsTrevi Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Trevi Therapeutics Q1 2023 Earnings Call TranscriptProvided by QuartrMay 11, 2023 ShareLink copied to clipboard.There are 6 speakers on the call. Operator00:00:00Afternoon, and welcome to the Trevy Therapeutics Q1 2023 Earnings Conference Call. At this time, all participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. Various remarks that management makes during this conference call about the company's future expectations, plans and prospects constitute forward looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Operator00:00:42Actual results may differ materially from those indicated by these forward looking statements as a result of various important factors, including those discussed In the Risk Factors section of the company's most recent quarterly report on Form 10 Q, which the company filed with the SEC this afternoon. In addition, any forward looking statement that represents the company's views only as of today and should not be relied upon as representing the company's views as of any subsequent date. While the company may elect to update these forward looking statements at some point in the future, the company specifically disclaims Any obligation to do so, even if its views change. I would now like to turn the conference call over to Jennifer Good, Trevy's President and CEO, please go ahead. Speaker 100:01:30Good afternoon, and thank you for joining our Q1 earnings call and business update. Joining me today on this call is Lisa Delfini, Trevi's Chief Financial Officer. Lisa and I have some prepared remarks, then we will open it up for questions. During the Q1, we continued to advance our clinical development plans for Huduvio for difficult to treat patients with chronic cough In idiopathic pulmonary fibrosis or IPF, other chronic cough indications and prurigo nodularis. Let me provide an update on each of our programs, beginning with our lead program in chronic cough and IPF. Speaker 100:02:07IPF is a serious end of life disease and chronic cough is a major cause of morbidity that significantly impacts a patient's quality of life. There are no approved therapies for the treatment of chronic cough and IPF, and the cough is often refractory to antitussive therapy. Patients with chronic cough and IPF can cough up to 1500 times per day, leading to fatigue, air hunger and increased anxiety. The chronic cough in IPF is also hypothesized to potentially enhance activation of pro fibrotic mechanisms and disease worsening. We are planning to conduct 2 studies in parallel during this next phase of development in our IPF chronic cough program. Speaker 100:02:52The first is a Phase IIb dose ranging trial that will study 3 active doses of HEDUVIO and placebo. The doses we are planning to study are 27, 54 and 108 milligrams BID. We are planning for a total N in the study of Approximately 150 to 200 subjects and dosing for approximately 6 weeks. We plan to conduct this study in multiple countries and sites To be able to complete enrollment in a timely manner. As you may be aware, there is a lot of development work going on with anti fibrotics in IPF patients. Speaker 100:03:28So we expect that enrollment will be competitive, and we are planning for that scenario. We have finalized the protocol for the dose ranging study and are preparing for various international submissions to regulatory authorities. We have also engaged our CRO and are in the final stages of country in site selection. We are planning on initiating this study in the second half of this year. In parallel, we are planning for a Phase 1b respiratory physiology study. Speaker 100:03:59Opioids have a generic risk of causing respiratory depression. This is not something we have seen in our safety data across our various studies to date, and there is literature that suggests that mixed agonist antagonist have a ceiling effect on the impact on respiration. However, given the respiration impairment of the IPF population, it is important that we characterize To what degree, if any, our drug causes respiratory depression in this patient population? Trevy is planning to conduct a Phase 1b inpatient study in IPF patients with cough that have varying levels of disease severity to determine if we see any clinically significant impact on respiratory depression. This study will help define the patient population for our pivotal program and ultimately the label. Speaker 100:04:49We have received FDA feedback on the planned Phase Ib study and are finalizing the protocol and preparing for the IND submission. We expect to initiate this study in the second half of this year as well. In addition to the preparations in IPF COF, We are also developing a protocol for a Phase 2 study in refractory chronic cough, also known as RCC. We believe that because HEYDUBIO works both centrally in the brain and peripherally in the lungs, HEYDUBIO has the potential to provide therapy across a range of chronic cough indications regardless of what the underlying disease is. We expect that this trial will look a lot like the Canal trial, Which was a dose escalating crossover design, and we expect to enroll approximately 60 subjects. Speaker 100:05:37There have been a lot of trials in RCC with only one mechanism which has seen some success, the P2X3s, which mechanistically work peripherally in the lung. However, we believe there is still a significant opportunity for a mechanism that works both centrally and peripherally and has the potential to provide strong and consistent efficacy in the most difficult to treat cough patients. In the most difficult to treat cough patients. We are leveraging the learnings from the prior development work in RCC by other Companies as we design our own study. Our cost data to date continues to garner a lot of attention at upcoming medical conferences With oral presentations of the data accepted at both the American Thoracic Society meeting beginning the end of next week As well as the American cough conference being held in June. Speaker 100:06:25We have also finalized a manuscript on the Canal trial results and have submitted it for publication. I think this speaks to the importance of the unmet medical need in these difficult to treat IPF patients And the medical community's interest in our program across cough indications. The other indication where we have ongoing work It's for the treatment of prigonodularis or PM, which is a serious and debilitating disease characterized by tapules and nodules on the skin as well as severe itching. In June of last year, we reported positive data in the Phase IIbIII PRISM trial in PN. The trial achieved statistical significance on the primary and all key secondary endpoints. Speaker 100:07:09During the Q1 of 2023, We completed the 1 year open label extension study that was associated with PRISM. We are currently analyzing the data from that study And we'll then seek an end of Phase II meeting with the FDA, which we expect to have later this year. After this meeting, we will determine next steps for the program. Finally, we are conducting a human abuse potential study, which is required for an NDA filing. Note that the parenteral version of nalbuphine is currently unscheduled in the U. Speaker 100:07:42S. By the Drug Enforcement Agency or DEA. The objective of this study is to compare the likability or abuse potential of oral nalbutene to an active comparator, which is butorphanol for this study. Butorphanol is a Schedule IV drug. The study is being conducted in 2 parts With the objective for the first part to characterize the various butorphanol doses and choose a dose appropriate for comparison against oral nalbuphine in Part 2. Speaker 100:08:12We have completed Part 1 of the study and have selected the detourphenol dose for the second part of the study. The second portion of the study is a randomized double blind active and placebo controlled five way crossover design To determine the abuse potential of 3 doses of oral nalbutorphine relative to the selected dose of butorphanol as well as placebo. There are 2 gating items to moving into Part 2 of this study. The first is a nationwide shortage of butorphanol. We are working with our CRO partner to secure the doses we need to conduct the study. Speaker 100:08:50And second, we intend to submit the results from Part 1 of the study To the FDA for any comments on dose selection of butorphanol before proceeding with Part 2 of the study. Assuming neither of these two items causes a significant delay, we expect top line results from the human abuse potential study by the end of this year. In closing, we are focused on execution to get these studies up and running. We will announce studies as they are initiated And provide more details on the study design, expected time lines and the all important name of the trial. I will now turn it over to Lisa to review our financial results, then we will open it up for any questions that you may have. Speaker 200:09:34Thank you, Jennifer, and good afternoon, everyone. The full financial results for the 3 months ended March 31, 2023, can be found in our press release $6,400,000 compared to a net loss of $7,300,000 for the same quarter in 2022. R and D expenses were $5,000,000 during Q1 of 2023 compared to $4,600,000 in the same quarter in 2022. The increase was primarily due to increased consulting and professional fees related to activities for the 3 planned chronic cough trials. This was offset by a decrease in clinical development expenses, reflecting the completion of both the blinded portion of the Phase 2bthree PRISM trial and the Phase 2 canal trial in 2022. Speaker 200:10:29G and A expenses were $2,600,000 during the Q1 of 2023 compared to $2,400,000 in the same period of 2022. The increase was primarily due to an increase in personnel related expenses and higher tax professional fees. Other income net was $1,200,000 for the Q1 2023 compared to other expense net of $300,000 in the same period of 2022. The change was primarily due to an increase in interest income. As of March 31, 2023, our cash, cash equivalents and marketable securities totaled $111,300,000 compared to $120,500,000 as of December 31, 2022. Speaker 200:11:12Subsequent to the end of the Q1, we elected to pay off our Term loan early. The amount paid was $6,500,000 and was previously classified as current on our balance sheet because the final payment was due in the Q1 of 2020 for according to its terms. The loan was with Silicon Valley Bank, now a division of First Citizens Bank, and it included restrictions related to keeping our corporate cash, Cash equivalents and marketable securities either at or managed by SVB. Given the recent events at SVB, we wanted to free ourselves of these restrictions. Our cash runway guidance remains unchanged since it had previously incorporated the pay down of the note in accordance with its terms. Speaker 200:11:53Accordingly, our cash, cash equivalents and marketable securities will enable us to fund our expenses into 2026. In the Q1, we burned approximately $9,000,000 of cash. That included completing the clinical work on the PN open label extension study And conducting Part 1 of the human abuse potential study. Excluding the payoff of the term note, we expect cash burn to be between This concludes our prepared remarks. I will now turn the call back over to the operator for Q and A. Operator00:12:35We will now begin the question and answer session. Our first question will come from Annabel Samimy with Stifel. You may now go ahead. Speaker 300:13:05Hi. This is Stacy dialing in for Annabel. Congrats on the quarter and just a few questions on our end. So the first is what was the rationale behind the decision to dose up to 162 in the Phase 1b respiratory trial and IPF when The Phase 2b are at lower doses? Another is, has the level of interest by outside partiers And your RCC significantly increased since the GSK acquisition of Bellis Health and how has that changed any of your TJ, thoughts around the indication? Speaker 100:13:40Yes. Okay. Thank you, Stacy, for the questions. So the Phase Ib trial, we're still finalizing the study design. Our current plan is to only dose to 108 milligrams, But that's some of the discussions that have been going back and forth with the FDA. Speaker 100:13:57So we think we only need to go to 108, but we'll see when we finalize it. As far as the RCC indication, yes, I mean, we obviously got a lot of inbound interest, I think. I'm going to state the obvious, but GSK certainly validated the importance of cough as a market and the unmet need there. I think with refractory chronic cough as well, there's just not been a lot of success there. You have the 2 players with the P2X3. Speaker 100:14:24So We kept quite busy from an investor perspective. We already are in a lot of discussions around sort of, with various strategics. Actually, I'll See several more over the next couple of months at conferences. So yes, I think that got everybody's attention and certainly turned the light back on Trevy because I think At that point, we're the only standalone cost company once Bellis is acquired. So it was good news for us. Operator00:14:58Our next question will come from Serge Belanger with Needham and Company. You may now go ahead. Speaker 400:15:06Hi, good afternoon. Just one question for us today. I think you received A new patent for nalbuten over the quarter. So maybe just give us an update on the overall IP for the product? Speaker 100:15:24Yes. Thank you, Serge. Yes, it was an important patent for us. We had filed a broad application. So we have 3 layers of patent One is the formulation patents that have been in place for the product. Speaker 100:15:35Those start to expire in roughly 2029. So the primary coverage that will extend that is through method of treatment patents. And we have a big broad application that we filed around various neurological coughs. What we did was take the data from the IPF Canal trial and actually pull out claims and prosecute a specific patent based The dosing, the data, etcetera. And that patent was issued. Speaker 100:16:02Coolie has helped us with that. We consider it to have broad claims in the patent. It goes to 2,039, will be Orange Book listable. So that becomes really sort of the core of the protection. On top of that, we also have filed others, what we call special population patents, data we've learned in the Hepatically impaired population, the elderly, that will be in the label around dosing. Speaker 100:16:25And those all have to play through. But if those get issued naturally into the label, That would move protection out even a couple of years beyond that. So getting that, that method of treatment in IPF chronic cough was super important for us. Operator00:16:49Our next question will come from Tom Smith with SVB Securities. You may now go ahead. Speaker 400:16:57Hi, this is Max Schwan Suk on for Tom Smith. Just one quick question from us. So what are the getting factors to initiate a Phase 2 Try out in RCC and the Phase 2b study in chronic cough in IPF. Currently, like you mentioned, packaging material shortage was like one of the factors. Is like that issue being like soft? Speaker 100:17:20Yes. So just to be clear, the materials issued I mentioned Butorphanol only affects our human abuse potential study. So that does not affect our Phase 2b dose ranging or our refractory chronic cough. We have plenty of drug supply with our own products. So just to be clear, that's sort of its own distinct issue. Speaker 100:17:43Factors of where we are now, I gave you sort of a good rundown of what we've accomplished. It's really the regulatory getting sign off from the regulatory authorities. We are running these studies Nationally, so we have to work through sort of the various regulators' comments. But we have final protocols. They'll be submitted for regulatory input, and that's really the swing factor we've said initiating in the second half of this year. Speaker 100:18:08Assuming that we get through the regulatory process pretty smoothly, it will be sooner. And if we get any comments back, we'll have to Adjust the protocol and go back to them. So it could be a little later in the second half. Speaker 400:18:21Got it. Thank you. You're welcome. Operator00:18:27Our next question will come from Mayank Mamtani with B. Riley Securities. You may now go ahead. Speaker 500:18:36Hi, this is William on for Mayank. Congratulations on the very nice quarter and thank you for taking our questions. So a couple from us. Just at a regulatory level, I guess, could you remind us of the current IND status for HEIDOVIO in chronic cough and how that's progressing? Speaker 100:18:56Thank you, William. Yes, so we are getting input with the FDA around this Phase Ib respiratory Physiology study, that will be our IND opening study. So we're preparing that now and that should be submitted shortly with the agency. But Fortunately, we've had a lot of good dialogue with them about the program. So we should be able to move that through and hopefully get the IND opened and get that Speaker 500:19:24Got you. Very helpful. And just thinking about RCC, When in terms of the patient population that you're planning to target, are you going completely broad sort of incorporating everybody or trying to do more of Targeting specific subgroups that you think Codovio may work best in and then maybe building out from there or some combination of that, if you could just speak to that, please? Speaker 100:19:48Yes. No, it's a good question. And this is where I'd mentioned in my comments, look, we don't need to sort of recreate the wheel here. There's been a lot of studies run-in RCC. And it's become pretty clear that an enrichment strategy there is quite effective. Speaker 100:20:03So we're working through those details, but we'll probably do a 2 to enrichment strategy of coffers greater than 20 and then some portion of coffers that are in the 10 to 19 range. We want to be mindful though because Bellis is out running these 2 pivotal studies with this enrichment criteria of greater than 20. If we don't have that as a requirement in our studies, we'll end up with all the mild coughers. So we don't want that to happen either. So we have put in some parameters around that to Get a more enriched population, but we will also study some of the lower coffers, which they're doing as well. Speaker 100:20:37They're doing a 3:one randomization. Speaker 400:20:41Right. Speaker 500:20:41Makes sense. And then one quick last one. I know you've mentioned that the open label PRISM, you're analyzing it, and then be meeting with the FDA. Any indication or color on when and where we might see that? And then any potential interactions you've had for that Or with that program? Speaker 100:21:01Yes. So William, I'm actually waiting to see that data myself. Our physician who's driving that along is sort of synthesizing that Down and we'll share it with the team. Where that gets presented, I think the most obvious next big derm conference is EADV, which is in the fall in Europe. We probably will do something in one of our press releases with some of the top line that we saw because people I know people are interested in that. Speaker 100:21:25As far as strategic conversations, we continue to be active there and move those along. But as we said, we as well want to have End of Phase II meeting. So we clarify exactly what's left in this program. So we certainly have been in conversations. We know the short list of interest. Speaker 100:21:44I think it's a matter of working our way through that FDA meeting and then reassessing at that point based on what we learn. Speaker 500:21:52Got it. That's all from us. Thank you for taking our questions again and congratulations again on a good quarter. Thanks. Speaker 100:21:59Thank you. Operator00:22:03Our next question will come from Sean Kim with Jones Trading. You may now go ahead. Speaker 400:22:10Yes. Hi. Thank you for taking my questions. So I guess one question on the modularis program. So What kind of feedback would you be expecting from the end of Phase 2 meeting in order for you to kind of move forward With the program. Speaker 400:22:27And I guess my second question is on the RCC side of things. So now does Bellas So at least being acquired by the larger Pharma GSK, has this shifted your thinking in terms of potentially commercializing other deal, The leading commercial efforts in the U. S. Or potentially partnering out given the European Union against the larger biopharmas? Thank you. Speaker 100:22:53Yes. So thank you, Sean. On PN, as far as feedback, the key question that we want to confirm is that The Phase IIbIII serves as one of our 2 pivotal studies. The agency agrees that we only need one additional trial. We're going to present the protocol for the next trial, which essentially looks just like the trial we just ran, possibly a little bit longer. Speaker 100:23:16So we just want to confirm that there's one more study. Here's what it looks like. There's some little CMC questions to nail down, Right. But nothing too major. So it's really pretty it's all really around that, that we're sort of there. Speaker 100:23:30As far as RCC, I don't think it's changed our thinking at all. I think we're continuing to sort of refine in our own minds where we're going to compete. And I think where the RCC market comes out For us is, we're looking at those severe difficult to treat patients. P2X3s work in about half the population, But don't work in about half the population. And we think that's because they essentially work on that peripheral chain. Speaker 100:23:55We believe because of our central mechanism That we should be able to work in more patients and have a bigger effect. So we our lead indication will be IPF, chronic Which we think will set us up for nice premium pricing and also other interstitial lung diseases. We think that we may be able to hold that At a pretty strong level for picking up the failures in the chronic cough market, which is about half that market. So it's Still a big opportunity. So that's how we think about it. Speaker 100:24:25As far as partnering that out, we say to partners all the time when they ask about that. I mean, we're a single asset And COF is our lead focus. So if people want the rights in the U. S. For that program, they're going to have to buy Trevy. Speaker 100:24:39We'll look at sort of Japan or possibly Europe, but in the U. S, they're just going to have to buy the company. Speaker 400:24:46Okay. That's very helpful. Thank you very much. Speaker 100:24:48Yes. Thank you, Speaker 500:24:53Sean. Operator00:24:57Our next question will be a follow-up from Annabel Samimy with Stifel. You may now go ahead. Speaker 100:25:06Hi, sorry about that. Our question was, Speaker 300:25:08previously answered. Thank you. Operator00:25:15I'm showing no further questions. This concludes our question and answer session. I would like to turn this conference call back over to Jennifer Goode for any closing remarks. Speaker 100:25:25We would like to thank everybody for participating in today's call. We have several upcoming conferences and medical meetings that we are participating in before summer gets fully underway. You can see them detailed in our earnings release issued today. I hope to see some of you at these meetings. Thank you.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallTrevi Therapeutics Q1 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Trevi Therapeutics Earnings HeadlinesNovo Nordisk A/S (NYSE:NVO) Earns "Market Perform" Rating from BMO Capital MarketsApril 19 at 3:02 AM | americanbankingnews.comNovo Nordisk Is Getting Absolutely DestroyedApril 19 at 1:25 AM | msn.comReal Americans Don’t Wait on Wall Street’s Next MoveWhat's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.April 19, 2025 | Premier Gold Co (Ad)Novo Nordisk: A Price Too Low To IgnoreApril 18 at 11:00 AM | seekingalpha.comNovo Nordisk A/S (NYSE:NVO) Receives Average Recommendation of "Hold" from AnalystsApril 18 at 2:49 AM | americanbankingnews.comNovo Nordisk downgraded by BMO as Eli Lilly gains ground in weight-loss drug raceApril 17 at 5:57 PM | finance.yahoo.comSee More Novo Nordisk A/S Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Trevi Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Trevi Therapeutics and other key companies, straight to your email. Email Address About Trevi TherapeuticsTrevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.View Trevi Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Archer Aviation Unveils NYC Network Ahead of Key Earnings Report3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions Ahead Upcoming Earnings Tesla (4/22/2025)Intuitive Surgical (4/22/2025)Verizon Communications (4/22/2025)Canadian National Railway (4/22/2025)Novartis (4/22/2025)RTX (4/22/2025)3M (4/22/2025)Capital One Financial (4/22/2025)General Electric (4/22/2025)Danaher (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 6 speakers on the call. Operator00:00:00Afternoon, and welcome to the Trevy Therapeutics Q1 2023 Earnings Conference Call. At this time, all participants will be in listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. Various remarks that management makes during this conference call about the company's future expectations, plans and prospects constitute forward looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Operator00:00:42Actual results may differ materially from those indicated by these forward looking statements as a result of various important factors, including those discussed In the Risk Factors section of the company's most recent quarterly report on Form 10 Q, which the company filed with the SEC this afternoon. In addition, any forward looking statement that represents the company's views only as of today and should not be relied upon as representing the company's views as of any subsequent date. While the company may elect to update these forward looking statements at some point in the future, the company specifically disclaims Any obligation to do so, even if its views change. I would now like to turn the conference call over to Jennifer Good, Trevy's President and CEO, please go ahead. Speaker 100:01:30Good afternoon, and thank you for joining our Q1 earnings call and business update. Joining me today on this call is Lisa Delfini, Trevi's Chief Financial Officer. Lisa and I have some prepared remarks, then we will open it up for questions. During the Q1, we continued to advance our clinical development plans for Huduvio for difficult to treat patients with chronic cough In idiopathic pulmonary fibrosis or IPF, other chronic cough indications and prurigo nodularis. Let me provide an update on each of our programs, beginning with our lead program in chronic cough and IPF. Speaker 100:02:07IPF is a serious end of life disease and chronic cough is a major cause of morbidity that significantly impacts a patient's quality of life. There are no approved therapies for the treatment of chronic cough and IPF, and the cough is often refractory to antitussive therapy. Patients with chronic cough and IPF can cough up to 1500 times per day, leading to fatigue, air hunger and increased anxiety. The chronic cough in IPF is also hypothesized to potentially enhance activation of pro fibrotic mechanisms and disease worsening. We are planning to conduct 2 studies in parallel during this next phase of development in our IPF chronic cough program. Speaker 100:02:52The first is a Phase IIb dose ranging trial that will study 3 active doses of HEDUVIO and placebo. The doses we are planning to study are 27, 54 and 108 milligrams BID. We are planning for a total N in the study of Approximately 150 to 200 subjects and dosing for approximately 6 weeks. We plan to conduct this study in multiple countries and sites To be able to complete enrollment in a timely manner. As you may be aware, there is a lot of development work going on with anti fibrotics in IPF patients. Speaker 100:03:28So we expect that enrollment will be competitive, and we are planning for that scenario. We have finalized the protocol for the dose ranging study and are preparing for various international submissions to regulatory authorities. We have also engaged our CRO and are in the final stages of country in site selection. We are planning on initiating this study in the second half of this year. In parallel, we are planning for a Phase 1b respiratory physiology study. Speaker 100:03:59Opioids have a generic risk of causing respiratory depression. This is not something we have seen in our safety data across our various studies to date, and there is literature that suggests that mixed agonist antagonist have a ceiling effect on the impact on respiration. However, given the respiration impairment of the IPF population, it is important that we characterize To what degree, if any, our drug causes respiratory depression in this patient population? Trevy is planning to conduct a Phase 1b inpatient study in IPF patients with cough that have varying levels of disease severity to determine if we see any clinically significant impact on respiratory depression. This study will help define the patient population for our pivotal program and ultimately the label. Speaker 100:04:49We have received FDA feedback on the planned Phase Ib study and are finalizing the protocol and preparing for the IND submission. We expect to initiate this study in the second half of this year as well. In addition to the preparations in IPF COF, We are also developing a protocol for a Phase 2 study in refractory chronic cough, also known as RCC. We believe that because HEYDUBIO works both centrally in the brain and peripherally in the lungs, HEYDUBIO has the potential to provide therapy across a range of chronic cough indications regardless of what the underlying disease is. We expect that this trial will look a lot like the Canal trial, Which was a dose escalating crossover design, and we expect to enroll approximately 60 subjects. Speaker 100:05:37There have been a lot of trials in RCC with only one mechanism which has seen some success, the P2X3s, which mechanistically work peripherally in the lung. However, we believe there is still a significant opportunity for a mechanism that works both centrally and peripherally and has the potential to provide strong and consistent efficacy in the most difficult to treat cough patients. In the most difficult to treat cough patients. We are leveraging the learnings from the prior development work in RCC by other Companies as we design our own study. Our cost data to date continues to garner a lot of attention at upcoming medical conferences With oral presentations of the data accepted at both the American Thoracic Society meeting beginning the end of next week As well as the American cough conference being held in June. Speaker 100:06:25We have also finalized a manuscript on the Canal trial results and have submitted it for publication. I think this speaks to the importance of the unmet medical need in these difficult to treat IPF patients And the medical community's interest in our program across cough indications. The other indication where we have ongoing work It's for the treatment of prigonodularis or PM, which is a serious and debilitating disease characterized by tapules and nodules on the skin as well as severe itching. In June of last year, we reported positive data in the Phase IIbIII PRISM trial in PN. The trial achieved statistical significance on the primary and all key secondary endpoints. Speaker 100:07:09During the Q1 of 2023, We completed the 1 year open label extension study that was associated with PRISM. We are currently analyzing the data from that study And we'll then seek an end of Phase II meeting with the FDA, which we expect to have later this year. After this meeting, we will determine next steps for the program. Finally, we are conducting a human abuse potential study, which is required for an NDA filing. Note that the parenteral version of nalbuphine is currently unscheduled in the U. Speaker 100:07:42S. By the Drug Enforcement Agency or DEA. The objective of this study is to compare the likability or abuse potential of oral nalbutene to an active comparator, which is butorphanol for this study. Butorphanol is a Schedule IV drug. The study is being conducted in 2 parts With the objective for the first part to characterize the various butorphanol doses and choose a dose appropriate for comparison against oral nalbuphine in Part 2. Speaker 100:08:12We have completed Part 1 of the study and have selected the detourphenol dose for the second part of the study. The second portion of the study is a randomized double blind active and placebo controlled five way crossover design To determine the abuse potential of 3 doses of oral nalbutorphine relative to the selected dose of butorphanol as well as placebo. There are 2 gating items to moving into Part 2 of this study. The first is a nationwide shortage of butorphanol. We are working with our CRO partner to secure the doses we need to conduct the study. Speaker 100:08:50And second, we intend to submit the results from Part 1 of the study To the FDA for any comments on dose selection of butorphanol before proceeding with Part 2 of the study. Assuming neither of these two items causes a significant delay, we expect top line results from the human abuse potential study by the end of this year. In closing, we are focused on execution to get these studies up and running. We will announce studies as they are initiated And provide more details on the study design, expected time lines and the all important name of the trial. I will now turn it over to Lisa to review our financial results, then we will open it up for any questions that you may have. Speaker 200:09:34Thank you, Jennifer, and good afternoon, everyone. The full financial results for the 3 months ended March 31, 2023, can be found in our press release $6,400,000 compared to a net loss of $7,300,000 for the same quarter in 2022. R and D expenses were $5,000,000 during Q1 of 2023 compared to $4,600,000 in the same quarter in 2022. The increase was primarily due to increased consulting and professional fees related to activities for the 3 planned chronic cough trials. This was offset by a decrease in clinical development expenses, reflecting the completion of both the blinded portion of the Phase 2bthree PRISM trial and the Phase 2 canal trial in 2022. Speaker 200:10:29G and A expenses were $2,600,000 during the Q1 of 2023 compared to $2,400,000 in the same period of 2022. The increase was primarily due to an increase in personnel related expenses and higher tax professional fees. Other income net was $1,200,000 for the Q1 2023 compared to other expense net of $300,000 in the same period of 2022. The change was primarily due to an increase in interest income. As of March 31, 2023, our cash, cash equivalents and marketable securities totaled $111,300,000 compared to $120,500,000 as of December 31, 2022. Speaker 200:11:12Subsequent to the end of the Q1, we elected to pay off our Term loan early. The amount paid was $6,500,000 and was previously classified as current on our balance sheet because the final payment was due in the Q1 of 2020 for according to its terms. The loan was with Silicon Valley Bank, now a division of First Citizens Bank, and it included restrictions related to keeping our corporate cash, Cash equivalents and marketable securities either at or managed by SVB. Given the recent events at SVB, we wanted to free ourselves of these restrictions. Our cash runway guidance remains unchanged since it had previously incorporated the pay down of the note in accordance with its terms. Speaker 200:11:53Accordingly, our cash, cash equivalents and marketable securities will enable us to fund our expenses into 2026. In the Q1, we burned approximately $9,000,000 of cash. That included completing the clinical work on the PN open label extension study And conducting Part 1 of the human abuse potential study. Excluding the payoff of the term note, we expect cash burn to be between This concludes our prepared remarks. I will now turn the call back over to the operator for Q and A. Operator00:12:35We will now begin the question and answer session. Our first question will come from Annabel Samimy with Stifel. You may now go ahead. Speaker 300:13:05Hi. This is Stacy dialing in for Annabel. Congrats on the quarter and just a few questions on our end. So the first is what was the rationale behind the decision to dose up to 162 in the Phase 1b respiratory trial and IPF when The Phase 2b are at lower doses? Another is, has the level of interest by outside partiers And your RCC significantly increased since the GSK acquisition of Bellis Health and how has that changed any of your TJ, thoughts around the indication? Speaker 100:13:40Yes. Okay. Thank you, Stacy, for the questions. So the Phase Ib trial, we're still finalizing the study design. Our current plan is to only dose to 108 milligrams, But that's some of the discussions that have been going back and forth with the FDA. Speaker 100:13:57So we think we only need to go to 108, but we'll see when we finalize it. As far as the RCC indication, yes, I mean, we obviously got a lot of inbound interest, I think. I'm going to state the obvious, but GSK certainly validated the importance of cough as a market and the unmet need there. I think with refractory chronic cough as well, there's just not been a lot of success there. You have the 2 players with the P2X3. Speaker 100:14:24So We kept quite busy from an investor perspective. We already are in a lot of discussions around sort of, with various strategics. Actually, I'll See several more over the next couple of months at conferences. So yes, I think that got everybody's attention and certainly turned the light back on Trevy because I think At that point, we're the only standalone cost company once Bellis is acquired. So it was good news for us. Operator00:14:58Our next question will come from Serge Belanger with Needham and Company. You may now go ahead. Speaker 400:15:06Hi, good afternoon. Just one question for us today. I think you received A new patent for nalbuten over the quarter. So maybe just give us an update on the overall IP for the product? Speaker 100:15:24Yes. Thank you, Serge. Yes, it was an important patent for us. We had filed a broad application. So we have 3 layers of patent One is the formulation patents that have been in place for the product. Speaker 100:15:35Those start to expire in roughly 2029. So the primary coverage that will extend that is through method of treatment patents. And we have a big broad application that we filed around various neurological coughs. What we did was take the data from the IPF Canal trial and actually pull out claims and prosecute a specific patent based The dosing, the data, etcetera. And that patent was issued. Speaker 100:16:02Coolie has helped us with that. We consider it to have broad claims in the patent. It goes to 2,039, will be Orange Book listable. So that becomes really sort of the core of the protection. On top of that, we also have filed others, what we call special population patents, data we've learned in the Hepatically impaired population, the elderly, that will be in the label around dosing. Speaker 100:16:25And those all have to play through. But if those get issued naturally into the label, That would move protection out even a couple of years beyond that. So getting that, that method of treatment in IPF chronic cough was super important for us. Operator00:16:49Our next question will come from Tom Smith with SVB Securities. You may now go ahead. Speaker 400:16:57Hi, this is Max Schwan Suk on for Tom Smith. Just one quick question from us. So what are the getting factors to initiate a Phase 2 Try out in RCC and the Phase 2b study in chronic cough in IPF. Currently, like you mentioned, packaging material shortage was like one of the factors. Is like that issue being like soft? Speaker 100:17:20Yes. So just to be clear, the materials issued I mentioned Butorphanol only affects our human abuse potential study. So that does not affect our Phase 2b dose ranging or our refractory chronic cough. We have plenty of drug supply with our own products. So just to be clear, that's sort of its own distinct issue. Speaker 100:17:43Factors of where we are now, I gave you sort of a good rundown of what we've accomplished. It's really the regulatory getting sign off from the regulatory authorities. We are running these studies Nationally, so we have to work through sort of the various regulators' comments. But we have final protocols. They'll be submitted for regulatory input, and that's really the swing factor we've said initiating in the second half of this year. Speaker 100:18:08Assuming that we get through the regulatory process pretty smoothly, it will be sooner. And if we get any comments back, we'll have to Adjust the protocol and go back to them. So it could be a little later in the second half. Speaker 400:18:21Got it. Thank you. You're welcome. Operator00:18:27Our next question will come from Mayank Mamtani with B. Riley Securities. You may now go ahead. Speaker 500:18:36Hi, this is William on for Mayank. Congratulations on the very nice quarter and thank you for taking our questions. So a couple from us. Just at a regulatory level, I guess, could you remind us of the current IND status for HEIDOVIO in chronic cough and how that's progressing? Speaker 100:18:56Thank you, William. Yes, so we are getting input with the FDA around this Phase Ib respiratory Physiology study, that will be our IND opening study. So we're preparing that now and that should be submitted shortly with the agency. But Fortunately, we've had a lot of good dialogue with them about the program. So we should be able to move that through and hopefully get the IND opened and get that Speaker 500:19:24Got you. Very helpful. And just thinking about RCC, When in terms of the patient population that you're planning to target, are you going completely broad sort of incorporating everybody or trying to do more of Targeting specific subgroups that you think Codovio may work best in and then maybe building out from there or some combination of that, if you could just speak to that, please? Speaker 100:19:48Yes. No, it's a good question. And this is where I'd mentioned in my comments, look, we don't need to sort of recreate the wheel here. There's been a lot of studies run-in RCC. And it's become pretty clear that an enrichment strategy there is quite effective. Speaker 100:20:03So we're working through those details, but we'll probably do a 2 to enrichment strategy of coffers greater than 20 and then some portion of coffers that are in the 10 to 19 range. We want to be mindful though because Bellis is out running these 2 pivotal studies with this enrichment criteria of greater than 20. If we don't have that as a requirement in our studies, we'll end up with all the mild coughers. So we don't want that to happen either. So we have put in some parameters around that to Get a more enriched population, but we will also study some of the lower coffers, which they're doing as well. Speaker 100:20:37They're doing a 3:one randomization. Speaker 400:20:41Right. Speaker 500:20:41Makes sense. And then one quick last one. I know you've mentioned that the open label PRISM, you're analyzing it, and then be meeting with the FDA. Any indication or color on when and where we might see that? And then any potential interactions you've had for that Or with that program? Speaker 100:21:01Yes. So William, I'm actually waiting to see that data myself. Our physician who's driving that along is sort of synthesizing that Down and we'll share it with the team. Where that gets presented, I think the most obvious next big derm conference is EADV, which is in the fall in Europe. We probably will do something in one of our press releases with some of the top line that we saw because people I know people are interested in that. Speaker 100:21:25As far as strategic conversations, we continue to be active there and move those along. But as we said, we as well want to have End of Phase II meeting. So we clarify exactly what's left in this program. So we certainly have been in conversations. We know the short list of interest. Speaker 100:21:44I think it's a matter of working our way through that FDA meeting and then reassessing at that point based on what we learn. Speaker 500:21:52Got it. That's all from us. Thank you for taking our questions again and congratulations again on a good quarter. Thanks. Speaker 100:21:59Thank you. Operator00:22:03Our next question will come from Sean Kim with Jones Trading. You may now go ahead. Speaker 400:22:10Yes. Hi. Thank you for taking my questions. So I guess one question on the modularis program. So What kind of feedback would you be expecting from the end of Phase 2 meeting in order for you to kind of move forward With the program. Speaker 400:22:27And I guess my second question is on the RCC side of things. So now does Bellas So at least being acquired by the larger Pharma GSK, has this shifted your thinking in terms of potentially commercializing other deal, The leading commercial efforts in the U. S. Or potentially partnering out given the European Union against the larger biopharmas? Thank you. Speaker 100:22:53Yes. So thank you, Sean. On PN, as far as feedback, the key question that we want to confirm is that The Phase IIbIII serves as one of our 2 pivotal studies. The agency agrees that we only need one additional trial. We're going to present the protocol for the next trial, which essentially looks just like the trial we just ran, possibly a little bit longer. Speaker 100:23:16So we just want to confirm that there's one more study. Here's what it looks like. There's some little CMC questions to nail down, Right. But nothing too major. So it's really pretty it's all really around that, that we're sort of there. Speaker 100:23:30As far as RCC, I don't think it's changed our thinking at all. I think we're continuing to sort of refine in our own minds where we're going to compete. And I think where the RCC market comes out For us is, we're looking at those severe difficult to treat patients. P2X3s work in about half the population, But don't work in about half the population. And we think that's because they essentially work on that peripheral chain. Speaker 100:23:55We believe because of our central mechanism That we should be able to work in more patients and have a bigger effect. So we our lead indication will be IPF, chronic Which we think will set us up for nice premium pricing and also other interstitial lung diseases. We think that we may be able to hold that At a pretty strong level for picking up the failures in the chronic cough market, which is about half that market. So it's Still a big opportunity. So that's how we think about it. Speaker 100:24:25As far as partnering that out, we say to partners all the time when they ask about that. I mean, we're a single asset And COF is our lead focus. So if people want the rights in the U. S. For that program, they're going to have to buy Trevy. Speaker 100:24:39We'll look at sort of Japan or possibly Europe, but in the U. S, they're just going to have to buy the company. Speaker 400:24:46Okay. That's very helpful. Thank you very much. Speaker 100:24:48Yes. Thank you, Speaker 500:24:53Sean. Operator00:24:57Our next question will be a follow-up from Annabel Samimy with Stifel. You may now go ahead. Speaker 100:25:06Hi, sorry about that. Our question was, Speaker 300:25:08previously answered. Thank you. Operator00:25:15I'm showing no further questions. This concludes our question and answer session. I would like to turn this conference call back over to Jennifer Goode for any closing remarks. Speaker 100:25:25We would like to thank everybody for participating in today's call. We have several upcoming conferences and medical meetings that we are participating in before summer gets fully underway. You can see them detailed in our earnings release issued today. I hope to see some of you at these meetings. Thank you.Read morePowered by